Ultrasmall Targeted Nanoparticles with Engineered Antibody Fragments for Imaging of HER2-overexpressing Breast Cancer

Marcello Marelli is a senior scientist at AstraZeneca where his research centres around protein engineering technologies aimed at creating new therapeutic medicines. Marcello has developed an expression system capable of site-specific incorporation of unnatural amino acids into target proteins. The unnatural amino acids contain unique chemical handles that enable conjugation chemistries for bioconjugations and the production of antibody drug conjugates, bispecific antibodies, and targeted nanoparticles. Marcello received his Ph.D. in cell biology from the University of Alberta, Canada where he studied the regulation of nucleo-cytoplasmic transport. During his post-doctoral fellowship at the Institute for Systems Biology (Seattle WA), he used proteomic and genomic analyses to understand the interconnectedness between cellular systems.